A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST).Ping Chi, William D. Tap, Li‐Xuan Qin et al.|Journal of Clinical Oncology|2020Cited by 21
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal TumorsPing Chi, William D. Tap, Niedzica Camacho et al.|Clinical Cancer Research|2022Cited by 16
A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS).Evan Rosenbaum, Sandra P. D’Angelo, Li‐Xuan Qin et al.|Journal of Clinical Oncology|2022Cited by 6
Association of immune-related adverse events (irAEs) with improved clinical outcome in sarcoma patients treated with immune checkpoint blockade (ICB).Evan Rosenbaum, William D. Tap, Kenneth Seier et al.|Journal of Clinical Oncology|2020Cited by 2
Supplementary Figure from Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal TumorsPing Chi, William D. Tap, Li‐Xuan Qin et al.|Unknown|2023Cited by 0